• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • SPORE In Prostate Cancer
    • External Funding Opportunities
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. A New Study to Treat Your Bladder Cancer

A New Study to Treat Your Bladder Cancer

Share this

A new study to treat your bladder cancer 

Lay Title: A study of ALT-803 plus BCG for bladder cancer for patients who have no previous treatment with BCG

Technical Title: A Study for Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Who Have Not Been Treated with BCG

Disease Type: High-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients who have not received treatment with BCG.

Basic information: The purpose of this research study is to look at the effectiveness of a combination treatment using ALT-803 (study drug) and BCG, compared to treatment with BCG alone. This study is for patients with non-muscle invasive bladder cancer (NMIBC) who have not received prior treatment with BCG. BCG is the standard treatment given to patients with NMIBC. In this study, patients will be randomized to receive either BCG alone, or BCG in combination with ALT-803.

Research Procedures (not a complete list): If you take part in this study, you will start by receiving up to six weekly doses of BCG plus ALT-803 or BCG alone. Both BCG and ALT-803 are given through intravesical therapy, which means the drug is given directly into the bladder through a catheter. On the days you receive treatment, after the BCG or BCG plus ALT-803 is placed in your bladder, you will be asked to stay at the treatment center for up to 4 hours for observation. You will also complete blood and urine tests for safety. If you receive ALT-803 in addition to BCG, extra blood and urine samples will be taken for research purposes.

Three months after your first dose, you will return for a response visit to see if your cancer has responded to treatment. During this visit, you will complete a cystoscopy and urine cytology testing. You will also provide blood and urine samples for research and safety testing, and complete a physical exam. You may need to complete more procedures depending on the results of these tests. If the tests show that the treatment has failed, you will stop receiving study treatment. If the tests show that you are responding to treatment, you will either receive six more weekly doses of treatment or 3 weekly doses of treatment every 3 months, depending on your response. After you finish treatment or are no longer eligible for treatment, you will continue to return for follow-up visits every 3 months through Month 24 to follow your disease status and to collect information on new cancer treatments you receive. 

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • Diagnosis of Non-Muscle Invasive Bladder Cancer of the transitional cell carcinoma high-risk subtype (high grade disease, T1, or carcinoma in situ [CIS])
  • Adequate lung function

Exclusion Criteria:

  • Prior treatment with BCG or known sensitivity to BCG.
  • Prior treatment with more than one dose of mitomycin-C or gemcitabine after surgery.

For More Detailed Information, Contact:

  • Karim Chamie, MD, Principal Investigator, Associate Professor-in-Residence of UCLA Urology
  • Ankush Sachdeva, Study Coordinator, (310) 794-3421

Read more about this study (NCT02138734) on ClinicalTrials.gov. 

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest